At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 42 enrolled
Drug / intervention
Fingolimoddrug
Likely dose
Fingolimod 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine
In Brief
A Phase 4 clinical trial evaluating Fingolimod for Multiple Sclerosis and Relapsing-Remitting. Completed, enrolled 42 participants across 11 sites.
Detailed Summary
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartOct 2012
Primary CompletionApr 2015
TodayJul 2026
First PostedApr 16, 2012
Enrollment StartOct 1, 2012
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.2 years ago
Interventions
Fingolimoddrug
Fingolimod 0.5mg orally once a day without food.